SARMs Crackdown! SARMs Control Act of 2018
Breaking News! SARMs Crackdown!
SARMs Control Act of 2018
Senator Orrin Hatch (R-UT) and Senator Sheldon Whitehouse (D-RI) introduced a new bill to give the Drug Enforcement Administration (DEA) more authority to get SARMS (selective androgen receptor modulators) off the market. Senator Hatch has been a longtime proponent of the supplement industry. The bill was introduced in the U.S. Senate on the night of Tuesday, April 24, 2018 and is called the SARMs Control Act of 2018. The bill will give authority to the DEA to remove illegal SARM products sold over the counter and online as controlled substances.
Selective androgen receptor modulators (SARMS) are synthetic anabolic drugs made to bind with androgen receptors in specific tissues such as muscle. Most anabolic steroids bind with androgen receptors throughout the body, which causes many of their side effects. While they bind with receptors in the muscle, they also bind with receptors in other tissues that affect sperm quality, skin oiliness and blood pressure. SARMs that bind with androgen receptors in muscle have little or no effect in other tissues, so they produce fewer side effects. Testosterone therapy is extremely popular in middle-aged and older men. SARMs could provide the benefits of testosterone with fewer side effects (Asian Journal of Andrology, published online December 16, 2013).
SARMs will likely be a multibillion-dollar blockbuster drug in the pharmaceutical industry. The Food and Drug Administration (FDA) may eventually approve SARMs for the treatment of muscle-wasting diseases such as HIV, cancer, hypogonadism and sarcopenia (muscle loss with aging). SARMs provide anabolic benefits in the absence of androgenic effects on the prostate, hair and skin.
References:
Press Release, 4/24/18. Website of Senator Orrin Hatch (R-UT) https://www.hatch.senate.gov/public/index.cfm/releases?ID=F1021776-7B96-4244-A82E-23A9931C99CD
Van Wagoner RM, Eichner A, Bhasin S, Deuster PA, Eichner D. Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet. JAMA 2017;318(20):2004-2010. doi:10.1001/jama.2017.17069
Coss CC, Jones A, Hancock ML, Steiner MS, Dalton JT. Selective androgen receptor modulators for the treatment of late onset male hypogonadism. Asian J Androl 2014; 16:256-61
DISCUSS THIS ARTICLE ON THE MD FORUM
FOLLOW MUSCULAR DEVELOPMENT ON:
FACEBOOK: MuscularDevelopment Magazine
TWITTER: @MuscularDevelop
INSTAGRAM: @MuscularDevelopment
YOUTUBE: http://bit.ly/2fvHgnZ